Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

The law in particular will affect CVS and UnitedHealth, both of which operate physical pharmacies in the state along with ...

Henry Gosebruch is now chief executive of the spinout, which has roughly $2.5 billion and plans to use dealmaking to build a ...

An ivonescimab-chemotherapy combination succeeded in a study in China. Elsewhere, the FDA asked Novavax for more COVID ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also ...

Alis Biosciences says its goal is to return to investors billions of dollars stuck on the balance sheets of “moribund” ...